THE INFLUENCE OF RITUXIMAB AND TOCILIZUMAB TREATMENT ON B-CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Suponitskaya, E. [1 ]
Aleksankin, A. [1 ]
Avdeeva, A. [1 ]
Aleksandrova, E. [1 ]
Novikov, A. [1 ]
Nasonov, E. [1 ]
机构：
[1] Nasonova Res Inst Rheumatol, Moscow, Russia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.3283
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0311
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [21] The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment
    Cambridge, G.
    Perry, H. C.
    Nogueira, L.
    Serre, G.
    Parsons, H. M.
    De La Torre, I.
    Dickson, M. C.
    Leandro, M. J.
    Edwards, J. C. W.
    [J]. JOURNAL OF AUTOIMMUNITY, 2014, 50 : 67 - 76
  • [22] ALTERATIONS OF PERIPHERAL BLOOD B-CELL SUBSETS IN EARLY RHEUMATOID ARTHRITIS
    Suponitskaya, E.
    Avdeeva, A.
    Aleksankin, A. A.
    Gerasimova, E.
    Aleksandrova, E.
    Popkova, T.
    Novikov, A. N.
    Karateev, D. K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 776 - 777
  • [23] Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis
    Truffot, Aurelie
    Gautier-Veyret, Elodie
    Baillet, Athan
    Jourdil, Jean-Francois
    Stanke-Labesque, Francoise
    Gottenberg, Jacques-Eric
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 (06) : 1090 - 1099
  • [24] B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
    Tuscano, Joseph M.
    Sands, Jacob
    [J]. BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 225 - 232
  • [25] Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response
    Breedveld, Ferdinand
    Agarwal, Sunil
    Yin, Ming
    Ren, Song
    Li, Nicole F.
    Shaw, Tim M.
    Davies, Brian E.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1119 - 1128
  • [26] CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
    Rosengren, Sanna
    Wei, Nathan
    Kalunian, Kenneth C.
    Kavanaugh, Arthur
    Boyle, David L.
    [J]. RHEUMATOLOGY, 2011, 50 (03) : 603 - 610
  • [27] Evaluation of tofacitinib on B cell subsets in patients with rheumatoid arthritis
    Wang, J.
    Ju, B.
    He, L.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 329 - 329
  • [28] DISRUPTION OF DOMINANT B-CELL/PLASMA CELL CLONES IN RHEUMATOID ARTHRITIS SYNOVIUM BY RITUXIMAB CORRELATES WITH TREATMENT RESPONSE
    Doorenspleet, M. E.
    Klarenbeek, P. L.
    Boumans, M. J.
    Thurlings, R. M.
    Esveldt, R. E.
    van Schaik, B. D.
    van Kampen, A. H.
    Gerlag, D. M.
    Baas, F.
    Tak, P. P.
    Plenge, R. M.
    de Vries, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 313 - 313
  • [29] Use of tocilizumab, abatacept or rituximab in rheumatoid arthritis
    Fahd, A.
    Noone, C.
    Stack, J.
    Daly, M.
    Eltahir, A.
    Harney, S.
    Ryan, J. G.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S199 - S199
  • [30] Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
    Doorenspleet, Marieke E.
    Klarenbeek, Paul L.
    Boumans, Maartje J.
    Thurlings, Rogier M.
    Esveldt, Rebecca E.
    van Schaik, Barbera D.
    van Kampen, Antoine H.
    Gerlag, Danielle M.
    Baas, Frank
    Tak, Paul-Peter
    Plenge, Robert M.
    de Vries, Niek
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S751 - S751
12345